Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 293

1.

Persistent HIV-infected cells in cerebrospinal fluid are associated with poorer neurocognitive performance.

Spudich S, Robertson KR, Bosch RJ, Gandhi RT, Cyktor JC, Mar H, Macatangay BJ, Lalama CM, Rinaldo C, Collier AC, Godfrey C, Eron JJ, McMahon D, Jacobs JL, Koontz D, Hogg E, Vecchio A, Mellors JW.

J Clin Invest. 2019 Jul 15;130. pii: 127413. doi: 10.1172/JCI127413. eCollection 2019 Jul 15.

2.

A Randomized, Placebo-Controlled, Pilot Clinical Trial of Dipyridamole to Decrease Hiv-Associated Chronic Inflammation.

Macatangay BJC, Jackson EK, Abebe KZ, Comer D, Cyktor J, Klamar-Blain C, Borowski L, Gillespie DG, Mellors JW, Rinaldo CR, Riddler SA.

J Infect Dis. 2019 Jul 6. pii: jiz344. doi: 10.1093/infdis/jiz344. [Epub ahead of print]

PMID:
31282542
3.

Allogeneic hematopoietic cell transplant for HIV patients with hematologic malignancies: the BMT CTN-0903/AMC-080 trial.

Ambinder RF, Wu J, Logan B, Durand CM, Shields R, Popat UR, Little RF, McMahon DK, Cyktor J, Mellors JW, Ayala E, Kaplan LD, Noy A, Jones RJ, Howard A, Forman SJ, Porter D, Arce-Lara C, Shaughnessy P, Sproat L, Hashmi SK, Mendizabal AM, Horowitz MM, Navarro WH, Alvarnas JC.

Biol Blood Marrow Transplant. 2019 Jul 4. pii: S1083-8791(19)30417-3. doi: 10.1016/j.bbmt.2019.06.033. [Epub ahead of print]

PMID:
31279752
4.

Clones of infected cells arise early in HIV-infected individuals.

Coffin JM, Wells DW, Zerbato JM, Kuruc JD, Guo S, Luke BT, Eron JJ, Bale M, Spindler J, Simonetti FR, Hill S, Kearney MF, Maldarelli F, Wu X, Mellors JW, Hughes SH.

JCI Insight. 2019 Jun 20;4(12). pii: 128432. doi: 10.1172/jci.insight.128432. eCollection 2019 Jun 20.

5.

Trends in Pretreatment HIV-1 Drug Resistance in Antiretroviral Therapy-naive Adults in South Africa, 2000-2016: A Pooled Sequence Analysis.

Chimukangara B, Lessells RJ, Rhee SY, Giandhari J, Kharsany ABM, Naidoo K, Lewis L, Cawood C, Khanyile D, Ayalew KA, Diallo K, Samuel R, Hunt G, Vandormael A, Stray-Pedersen B, Gordon M, Makadzange T, Kiepiela P, Ramjee G, Ledwaba J, Kalimashe M, Morris L, Parikh UM, Mellors JW, Shafer RW, Katzenstein D, Moodley P, Gupta RK, Pillay D, Abdool Karim SS, de Oliveira T.

EClinicalMedicine. 2019 Mar 18;9:26-34. doi: 10.1016/j.eclinm.2019.03.006. eCollection 2019 Mar.

6.

Telemedicine and Infectious Diseases Practice: A Leap Forward or a Step Back?

Abdel-Massih RC, Mellors JW.

Open Forum Infect Dis. 2019 Apr 20;6(5):ofz196. doi: 10.1093/ofid/ofz196. eCollection 2019 May.

7.

Dapivirine vaginal ring for HIV prevention: modelling health outcomes, drug resistance and cost-effectiveness.

Glaubius R, Ding Y, Penrose KJ, Hood G, Engquist E, Mellors JW, Parikh UM, Abbas UL.

J Int AIDS Soc. 2019 May;22(5):e25282. doi: 10.1002/jia2.25282.

8.

Brief Report: HIV Antibodies Decline During Antiretroviral Therapy but Remain Correlated With HIV DNA and HIV-Specific T-Cell Responses.

Keating SM, Jones RB, Lalama CM, Bosch RJ, McMahon D, Hampton D, Cyktor J, Eron JJ, Mellors JW, Busch MP, Gandhi RT; ACTG 5321 Team.

J Acquir Immune Defic Syndr. 2019 Aug 15;81(5):594-599. doi: 10.1097/QAI.0000000000002080.

PMID:
31045647
9.

Assessing intra-lab precision and inter-lab repeatability of outgrowth assays of HIV-1 latent reservoir size.

Rosenbloom DIS, Bacchetti P, Stone M, Deng X, Bosch RJ, Richman DD, Siliciano JD, Mellors JW, Deeks SG, Ptak RG, Hoh R, Keating SM, Dimapasoc M, Massanella M, Lai J, Sobolewski MD, Kulpa DA, Busch MP; Reservoir Assay Validation and Evaluation Network (RAVEN) Study Group.

PLoS Comput Biol. 2019 Apr 12;15(4):e1006849. doi: 10.1371/journal.pcbi.1006849. eCollection 2019 Apr.

10.

Recommendations for analytical antiretroviral treatment interruptions in HIV research trials-report of a consensus meeting.

Julg B, Dee L, Ananworanich J, Barouch DH, Bar K, Caskey M, Colby DJ, Dawson L, Dong KL, Dubé K, Eron J, Frater J, Gandhi RT, Geleziunas R, Goulder P, Hanna GJ, Jefferys R, Johnston R, Kuritzkes D, Li JZ, Likhitwonnawut U, van Lunzen J, Martinez-Picado J, Miller V, Montaner LJ, Nixon DF, Palm D, Pantaleo G, Peay H, Persaud D, Salzwedel J, Salzwedel K, Schacker T, Sheikh V, Søgaard OS, Spudich S, Stephenson K, Sugarman J, Taylor J, Tebas P, Tiemessen CT, Tressler R, Weiss CD, Zheng L, Robb ML, Michael NL, Mellors JW, Deeks SG, Walker BD.

Lancet HIV. 2019 Apr;6(4):e259-e268. doi: 10.1016/S2352-3018(19)30052-9. Epub 2019 Mar 15. Review.

PMID:
30885693
11.

Longitudinal changes in HIV DNA in HIV controllers: what do they mean?

Hsu DC, Mellors JW.

J Int AIDS Soc. 2019 Feb;22(2):e25254. doi: 10.1002/jia2.25254. No abstract available.

12.

Naïve CD4+ T Cells Harbor a Large Inducible Reservoir of Latent, Replication-Competent HIV-1.

Zerbato JM, McMahon DK, Sobolewski MD, Mellors JW, Sluis-Cremer N.

Clin Infect Dis. 2019 Feb 7. doi: 10.1093/cid/ciz108. [Epub ahead of print]

PMID:
30753360
13.

Blockade of the PD-1 axis alone is not sufficient to activate HIV-1 virion production from CD4+ T cells of individuals on suppressive ART.

Bui JK, Cyktor JC, Fyne E, Campellone S, Mason SW, Mellors JW.

PLoS One. 2019 Jan 25;14(1):e0211112. doi: 10.1371/journal.pone.0211112. eCollection 2019.

14.

A Simpler and More Sensitive Single-Copy HIV-1 RNA Assay for Quantification of Persistent HIV-1 Viremia in Individuals on Suppressive Antiretroviral Therapy.

Tosiano MA, Jacobs JL, Shutt KA, Cyktor JC, Mellors JW.

J Clin Microbiol. 2019 Feb 27;57(3). pii: e01714-18. doi: 10.1128/JCM.01714-18. Print 2019 Mar.

PMID:
30626659
15.

Regulatory T cells: the ultimate HIV reservoir?

Rocco J, Mellors JW, Macatangay BJ.

J Virus Erad. 2018 Oct 1;4(4):209-214.

16.

Randomized Clinical Trial to Assess the Impact of the Broadly Neutralizing HIV-1 Monoclonal Antibody VRC01 on HIV-1 Persistence in Individuals on Effective ART.

Riddler SA, Zheng L, Durand CM, Ritz J, Koup RA, Ledgerwood J, Bailer RT, Koletar SL, Eron JJ, Keefer MC, Macatangay BJC, Cyktor JC, Mellors JW; AIDS Clinical Trials Group A5342 Protocol Team .

Open Forum Infect Dis. 2018 Oct 20;5(10):ofy242. doi: 10.1093/ofid/ofy242. eCollection 2018 Oct.

17.

Clinical and Virologic Outcomes Following Initiation of Antiretroviral Therapy Among Seroconverters in the MTN-020/ASPIRE Phase III Trial of the Dapivirine Vaginal Ring.

Riddler SA, Balkus JE, Parikh UM, Mellors JW, Akello C, Dadabhai S, Mhlanga F, Ramjee G, Mayo AJ, Livant E, Heaps AL, O'Rourke C, Baeten JM; MTN-015; MTN-020/ASPIRE Study Teams.

Clin Infect Dis. 2018 Oct 22. doi: 10.1093/cid/ciy909. [Epub ahead of print]

PMID:
30346511
18.

Ongoing HIV Replication During ART Reconsidered.

Kearney MF, Wiegand A, Shao W, McManus WR, Bale MJ, Luke B, Maldarelli F, Mellors JW, Coffin JM.

Open Forum Infect Dis. 2017 Sep 19;4(3):ofx173. doi: 10.1093/ofid/ofx173. eCollection 2017 Summer.

19.

Reply to Suthar et al.

Wallis CL, Godfrey C, Fitzgibbon JE, Mellors JW.

J Infect Dis. 2019 Jan 29;219(4):673-674. doi: 10.1093/infdis/jiy558. No abstract available.

PMID:
30307562
20.

Measurement of plasma HIV-1 RNA below the limit of quantification (<20 copies/mL) of commercial assays with the integrase HIV RNA single-copy assay.

Margot N, Koontz D, McCallister S, Mellors JW, Callebaut C.

J Clin Virol. 2018 Nov;108:50-52. doi: 10.1016/j.jcv.2018.09.003. Epub 2018 Sep 10.

PMID:
30240941
21.

The Control of HIV After Antiretroviral Medication Pause (CHAMP) Study: Posttreatment Controllers Identified From 14 Clinical Studies.

Namazi G, Fajnzylber JM, Aga E, Bosch RJ, Acosta EP, Sharaf R, Hartogensis W, Jacobson JM, Connick E, Volberding P, Skiest D, Margolis D, Sneller MC, Little SJ, Gianella S, Smith DM, Kuritzkes DR, Gulick RM, Mellors JW, Mehraj V, Gandhi RT, Mitsuyasu R, Schooley RT, Henry K, Tebas P, Deeks SG, Chun TW, Collier AC, Routy JP, Hecht FM, Walker BD, Li JZ.

J Infect Dis. 2018 Nov 5;218(12):1954-1963. doi: 10.1093/infdis/jiy479.

PMID:
30085241
22.

Associations between HIV-1 DNA copy number, proviral transcriptional activity, and plasma viremia in individuals off or on suppressive antiretroviral therapy.

Hong F, Jacobs JL, Aga E, Cillo AR, Fyne E, Koontz DL, Zheng L, Mellors JW.

Virology. 2018 Aug;521:51-57. doi: 10.1016/j.virol.2018.05.018. Epub 2018 Jun 4.

PMID:
29879542
23.

Reply to Kojima and Klausner.

Nachega JB, Sam-Agudu NA, Mofenson LM, Schechter M, Mellors JW.

Clin Infect Dis. 2018 Oct 15;67(9):1469-1470. doi: 10.1093/cid/ciy345. No abstract available.

PMID:
29718304
24.

Use of External Quality Control Material for HIV-1 RNA Testing To Assess the Comparability of Data Generated in Separate Laboratories and the Stability of HIV-1 RNA in Samples after Prolonged Storage.

Jennings C, Wager CG, Scianna SR, Zaccaro DJ, Couzens A, Mellors JW, Coombs RW, Bremer JW.

J Clin Microbiol. 2018 May 25;56(6). pii: e00120-18. doi: 10.1128/JCM.00120-18. Print 2018 Jun.

25.

Frequent cross-resistance to rilpivirine among subtype C HIV-1 from first-line antiretroviral therapy failures in South Africa.

Penrose KJ, Brumme CJ, Scoulos-Hanson M, Hamanishi K, Gordon K, Viana RV, Wallis CL, Harrigan PR, Mellors JW, Parikh UM.

Antivir Chem Chemother. 2018 Jan-Dec;26:2040206618762985. doi: 10.1177/2040206618762985.

26.

Cumulative Antiretroviral Exposure Measured in Hair Is Not Associated With Measures of HIV Persistence or Inflammation Among Individuals on Suppressive ART.

Gandhi M, Gandhi RT, Stefanescu A, Bosch RJ, Cyktor JC, Horng H, Louie A, Phung N, Eron JJ, Hogg E, Macatangay BJC, Hensel C, Fletcher CV, Mellors JW, McMahon DK; A5321 Team.

J Infect Dis. 2018 Jun 20;218(2):234-238. doi: 10.1093/infdis/jiy011.

27.

Lower pre-ART intra-participant HIV-1 pol diversity may not be associated with virologic failure in adults.

Kearney MF, Spindler J, Wiegand A, Shao W, Haubrich R, Riddler S, Lalama CM, Hughes MD, Coffin JM, Mellors JW.

PLoS One. 2018 Jan 25;13(1):e0190438. doi: 10.1371/journal.pone.0190438. eCollection 2018.

28.

Rapid decline of HIV-1 DNA and RNA in infants starting very early antiretroviral therapy may pose a diagnostic challenge.

Veldsman KA, Maritz J, Isaacs S, Katusiime MG, Janse van Rensburg A, Laughton B, Mellors JW, Cotton MF, van Zyl GU.

AIDS. 2018 Mar 13;32(5):629-634. doi: 10.1097/QAD.0000000000001739.

29.

Blood biomarkers of expressed and inducible HIV-1.

Cillo AR, Hong F, Tsai A, Irrinki A, Kaur J, Sloan DD, Follen M, Geleziunas R, Cihlar T, Win SS, Murry JP, Mellors JW.

AIDS. 2018 Mar 27;32(6):699-708. doi: 10.1097/QAD.0000000000001748.

30.

Impact of HLA Class I Alleles on Timing of HIV Rebound After Antiretroviral Treatment Interruption.

Park YJ, Etemad B, Ahmed H, Naranbhai V, Aga E, Bosch RJ, Mellors JW, Kuritzkes DR, Para M, Gandhi RT, Carrington M, Li JZ.

Pathog Immun. 2017;2(3):431-445. doi: 10.20411/pai.v2i3.222. Epub 2017 Nov 27.

31.

Achieving Viral Suppression in 90% of People Living With Human Immunodeficiency Virus on Antiretroviral Therapy in Low- and Middle-Income Countries: Progress, Challenges, and Opportunities.

Nachega JB, Sam-Agudu NA, Mofenson LM, Schechter M, Mellors JW.

Clin Infect Dis. 2018 May 2;66(10):1487-1491. doi: 10.1093/cid/ciy008.

PMID:
29324994
32.

The Argument Against Testing for INSTI Resistance in Treatment Naive Patients.

Veldkamp PJ, Mellors JW, Halvas EK.

Clin Infect Dis. 2018 May 17;66(11):1820-1821. doi: 10.1093/cid/ciy015. No abstract available.

PMID:
29324987
33.

Key Factors Influencing the Emergence of Human Immunodeficiency Virus Drug Resistance in Low- and Middle-Income Countries.

Wallis CL, Godfrey C, Fitzgibbon JE, Mellors JW.

J Infect Dis. 2017 Dec 1;216(suppl_9):S851-S856. doi: 10.1093/infdis/jix409. Review.

34.

HIV-1 persistence following extremely early initiation of antiretroviral therapy (ART) during acute HIV-1 infection: An observational study.

Henrich TJ, Hatano H, Bacon O, Hogan LE, Rutishauser R, Hill A, Kearney MF, Anderson EM, Buchbinder SP, Cohen SE, Abdel-Mohsen M, Pohlmeyer CW, Fromentin R, Hoh R, Liu AY, McCune JM, Spindler J, Metcalf-Pate K, Hobbs KS, Thanh C, Gibson EA, Kuritzkes DR, Siliciano RF, Price RW, Richman DD, Chomont N, Siliciano JD, Mellors JW, Yukl SA, Blankson JN, Liegler T, Deeks SG.

PLoS Med. 2017 Nov 7;14(11):e1002417. doi: 10.1371/journal.pmed.1002417. eCollection 2017 Nov.

35.

T-cell responses targeting HIV Nef uniquely correlate with infected cell frequencies after long-term antiretroviral therapy.

Thomas AS, Jones KL, Gandhi RT, McMahon DK, Cyktor JC, Chan D, Huang SH, Truong R, Bosque A, Macedo AB, Kovacs C, Benko E, Eron JJ, Bosch RJ, Lalama CM, Simmens S, Walker BD, Mellors JW, Jones RB.

PLoS Pathog. 2017 Sep 20;13(9):e1006629. doi: 10.1371/journal.ppat.1006629. eCollection 2017 Sep.

36.

No evidence of HIV replication in children on antiretroviral therapy.

Van Zyl GU, Katusiime MG, Wiegand A, McManus WR, Bale MJ, Halvas EK, Luke B, Boltz VF, Spindler J, Laughton B, Engelbrecht S, Coffin JM, Cotton MF, Shao W, Mellors JW, Kearney MF.

J Clin Invest. 2017 Oct 2;127(10):3827-3834. doi: 10.1172/JCI94582. Epub 2017 Sep 11.

37.

Treatment with integrase inhibitor suggests a new interpretation of HIV RNA decay curves that reveals a subset of cells with slow integration.

Cardozo EF, Andrade A, Mellors JW, Kuritzkes DR, Perelson AS, Ribeiro RM.

PLoS Pathog. 2017 Jul 5;13(7):e1006478. doi: 10.1371/journal.ppat.1006478. eCollection 2017 Jul.

38.

Clinical Trial of the Anti-PD-L1 Antibody BMS-936559 in HIV-1 Infected Participants on Suppressive Antiretroviral Therapy.

Gay CL, Bosch RJ, Ritz J, Hataye JM, Aga E, Tressler RL, Mason SW, Hwang CK, Grasela DM, Ray N, Cyktor JC, Coffin JM, Acosta EP, Koup RA, Mellors JW, Eron JJ; AIDS Clinical Trials 5326 Study Team.

J Infect Dis. 2017 Jun 1;215(11):1725-1733. doi: 10.1093/infdis/jix191.

39.

Levels of HIV-1 persistence on antiretroviral therapy are not associated with markers of inflammation or activation.

Gandhi RT, McMahon DK, Bosch RJ, Lalama CM, Cyktor JC, Macatangay BJ, Rinaldo CR, Riddler SA, Hogg E, Godfrey C, Collier AC, Eron JJ, Mellors JW; ACTG A5321 Team.

PLoS Pathog. 2017 Apr 20;13(4):e1006285. doi: 10.1371/journal.ppat.1006285. eCollection 2017 Apr.

40.

Single-cell analysis of HIV-1 transcriptional activity reveals expression of proviruses in expanded clones during ART.

Wiegand A, Spindler J, Hong FF, Shao W, Cyktor JC, Cillo AR, Halvas EK, Coffin JM, Mellors JW, Kearney MF.

Proc Natl Acad Sci U S A. 2017 May 2;114(18):E3659-E3668. doi: 10.1073/pnas.1617961114. Epub 2017 Apr 17.

41.

Toll-Like Receptor Agonists: Can They Exact a Toll on Human Immunodeficiency Virus Persistence?

Cyktor JC, Mellors JW.

Clin Infect Dis. 2017 Jun 15;64(12):1696-1698. doi: 10.1093/cid/cix204. No abstract available.

PMID:
28329288
42.

Proviruses with identical sequences comprise a large fraction of the replication-competent HIV reservoir.

Bui JK, Sobolewski MD, Keele BF, Spindler J, Musick A, Wiegand A, Luke BT, Shao W, Hughes SH, Coffin JM, Kearney MF, Mellors JW.

PLoS Pathog. 2017 Mar 22;13(3):e1006283. doi: 10.1371/journal.ppat.1006283. eCollection 2017 Mar.

43.

Ex vivo activation of CD4+ T-cells from donors on suppressive ART can lead to sustained production of infectious HIV-1 from a subset of infected cells.

Bui JK, Halvas EK, Fyne E, Sobolewski MD, Koontz D, Shao W, Luke B, Hong FF, Kearney MF, Mellors JW.

PLoS Pathog. 2017 Feb 22;13(2):e1006230. doi: 10.1371/journal.ppat.1006230. eCollection 2017 Feb.

44.

Future technologies for monitoring HIV drug resistance and cure.

Parikh UM, McCormick K, van Zyl G, Mellors JW.

Curr Opin HIV AIDS. 2017 Mar;12(2):182-189. doi: 10.1097/COH.0000000000000344. Review.

PMID:
28059958
45.

Ultrasensitive single-genome sequencing: accurate, targeted, next generation sequencing of HIV-1 RNA.

Boltz VF, Rausch J, Shao W, Hattori J, Luke B, Maldarelli F, Mellors JW, Kearney MF, Coffin JM.

Retrovirology. 2016 Dec 20;13(1):87. doi: 10.1186/s12977-016-0321-6.

46.

Performance of Celera RUO integrase resistance assay across multiple HIV-1 subtypes.

Wallis CL, Viana RV, Saravanan S, Silva de Jesus C, Zeh C, Halvas EK, Mellors JW.

J Virol Methods. 2017 Mar;241:41-45. doi: 10.1016/j.jviromet.2016.12.008. Epub 2016 Dec 16.

47.

Frequent Cross-Resistance to Dapivirine in HIV-1 Subtype C-Infected Individuals after First-Line Antiretroviral Therapy Failure in South Africa.

Penrose KJ, Wallis CL, Brumme CJ, Hamanishi KA, Gordon KC, Viana RV, Harrigan PR, Mellors JW, Parikh UM.

Antimicrob Agents Chemother. 2017 Jan 24;61(2). pii: e01805-16. doi: 10.1128/AAC.01805-16. Print 2017 Feb.

48.

A Cure for HIV Infection: "Not in My Lifetime" or "Just Around the Corner"?

Lederman MM, Cannon PM, Currier JS, June CH, Kiem HP, Kuritzkes DR, Lewin SR, Margolis DM, McCune JM, Mellors JW, Schacker TW, Sekaly RP, Tebas P, Walker BD, Douek DC.

Pathog Immun. 2016 Spring;1(1):154-164.

49.

HIV persistence in the CNS: the final frontier for a cure?

Lewin SR, Mellors JW.

J Virus Erad. 2016 Oct 5;2(4):242. No abstract available.

50.

Deciphering the Effects of Injectable Pre-exposure Prophylaxis for Combination Human Immunodeficiency Virus Prevention.

Glaubius RL, Parikh UM, Hood G, Penrose KJ, Bendavid E, Mellors JW, Abbas UL.

Open Forum Infect Dis. 2016 Jun 16;3(3):ofw125. eCollection 2016 Sep.

Supplemental Content

Loading ...
Support Center